进博会观察|西门子医疗：以本土研发制造提升中国高端医疗实力

Core Viewpoint - The article highlights Siemens Healthineers' commitment to localizing its operations in China while introducing innovative medical technologies, aiming to transition from a product provider to a value partner in the healthcare sector [2][5][8]. Group 1: Localization and Innovation - Siemens Healthineers showcased multiple new products, including photon-counting CT devices, at the 8th China International Import Expo, emphasizing its strategy to bring global innovations to the Chinese market [2][3]. - The company has achieved over 80% localization in production, with more than 130 products manufactured locally, and plans to further enhance its local manufacturing capabilities [5][6]. - The introduction of the world's first photon-counting CT, NAEOTOM Alpha, represents a significant advancement, with plans for two new models to be produced in China by 2026 [5]. Group 2: Advanced Medical Solutions - The ARTIS icono ceiling Xpand system features a unique 0.5mm precision laser puncture navigation, significantly improving the accuracy of interventions for lung and liver cancers [3]. - The Biograph One PET/MR system allows simultaneous imaging of structural, functional, and molecular data, reducing scan times to 17 minutes, thus enhancing efficiency and accessibility [3]. - The SmART adaptive radiotherapy solution, designed for Chinese clinical needs, enables personalized treatment adjustments in real-time, improving patient outcomes [4]. Group 3: Strategic Collaborations and Future Plans - Siemens Healthineers has formed strategic partnerships, such as with Novartis, to explore integrated systems for molecular imaging and radioligand therapy, reinforcing its role as a value partner [7]. - The company is expanding its R&D and manufacturing base in Shenzhen, with an investment exceeding 1 billion RMB, aiming to triple the facility's capacity by 2027 [6]. - Siemens Healthineers plans to deepen its integration with clinical practices and enhance its sustainability efforts, focusing on creating a more open innovation ecosystem in China's healthcare sector [8].